529508-56-3

Basic information

• Product Name: 4-Chloro-5-Methylpyrrolo[...
• Synonyms: 4-Chloro-5-Methylpyrrolo[...;4-Chloro-5-Methylpyrrolo[1,2-f][1,2,4]triazine;4-Chloro-5-Methylpyrrolo[2,1-f][1,2,4]triazine
• CAS NO: 529508-56-3
• Molecular Formula: C₇H₆ClN₃
• Molecular Weight: 167.59564
• Mol File: 529508-56-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.43±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -2.29±0.30(Predicted)
• CAS DataBase Reference: 4-Chloro-5-Methylpyrrolo[...(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-5-Methylpyrrolo[...(529508-56-3)
• EPA Substance Registry System: 4-Chloro-5-Methylpyrrolo[...(529508-56-3)

Safety Data

• Hazardous Substances Data: 529508-56-3(Hazardous Substances Data)

Usage

General Description

4-Chloro-5-Methylpyrrolo[2,1-f][1,2,4]Triazine, also known as CMPT, is a chemical compound that belongs to the class of pyrrolopyrimidine derivatives. It is used in the field of medicinal chemistry for the development of new pharmaceuticals, particularly in the treatment of cancer. CMPT has been studied for its potential to inhibit the activity of enzymes involved in cancer cell growth and proliferation. Additionally, it has also been investigated for its antibacterial and antiviral properties. The compound's unique structure and chemical properties make it a promising candidate for further research and development in the field of drug discovery and design.

Upstream product

• 1392140-56-5 ethyl 1-amino-3-methyl-1H-pyrrole-2-carboxylate 
• 3284-47-7 ethyl 3-methyl-1H-pyrrole-2-carboxylate 
• 310435-15-5 5-methyl-4-oxo-3,4-dihydro-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid 
• 310431-29-9 5-methyl-4-oxo-3,4-dihydro-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester 
• 529508-54-1 C₇H₇N₃O 
• 310435-15-5 C₈H₇N₃O₃ 
• 427878-70-4 ethyl 4-hydroxy-5-methylpyrrolo[2,1-f ][1,2,4]-triazine-6-carboxylate 
• 427878-69-1 1-amino-3-methyl-1H-pyrrole-2,4-dicarboxylic acid diethyl ester 
• 5448-16-8 3-methyl-1H-pyrrole-2,4-dicarboxylic acid diethyl ester 
• 529508-54-1 5-methylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one 

Downstream Products

• 529508-57-4 5-(bromomethyl)-4-chloropyrrolo[2,1-f][1,2,4]triazine 
• 859855-15-5 4-(3-methoxyphenylamino)pyrrolo[2,1-f][1,2,4]triazin-5-ylmethyl triethylammonium bromide 
• 888720-34-1 4-(2-fluoro-4-nitrophenoxy)-5-methylpyrrolo[2,1-f][1,2,4]triazine 
• 859205-93-9 (S)-2-{4-[3-chloro-4-(3-fluoro-benzyloxy)-5 phenylamino]-pyrrolo[2,1-f][1,2,4]triazin-5-ylmethoxy methyl}-morpholine-4-carboxylic acid tert-butyl ester 

Relevant articles and documents

PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF

The present invention relates to a group of pyrrolo[2, 1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and an application thereof in the preparation of a drug that serves as an HER2 inhibitor. Specifically, the present invention relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

Development of a practical synthesis of a functionalized pyrrolo[2,1-f][1,2,4]triazine nucleus

Functionalized pyrrolotriazine 1b is a key heterocyclic building block in the synthesis of BMS-690514, a potent anticancer agent. Described herein are our development activities that led to the efficient preparation of 1b on a large scale. The key transformations include a selective C-alkylation of an oxalacetate salt with a hydrazonyl bromide to form a 2-hydrazonoethyl-3- oxosuccinate, followed by cyclodehydration to an aminopyrrole. Subsequent deprotection and condensation with formamidine afforded the pyrrolotriazine scaffold. Further elaboration of this core provided the desired pyrrolotriazinyl amine.

C-5 Modified indazolylpyrrolotriazines

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.